Advertisement
Advertisement
U.S. markets close in 6 hours 24 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Marvel Biosciences Corp. (MRVL.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.22000.0000 (0.00%)
As of 03:46PM EST. Market open.
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.2200
Open0.1850
Bid0.1850 x N/A
Ask0.2400 x N/A
Day's Range0.1850 - 0.2200
52 Week Range0.1800 - 0.3900
Volume6,000
Avg. Volume23,410
Market Cap7.169M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.1400
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for MRVL.V

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Newsfile

      Marvel Biosciences Completes Manufacturing Engineering Run of Lead Asset MB-204

      Calgary, Alberta--(Newsfile Corp. - December 16, 2021) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announces it has successfully completed a multi-kilogram engineering run of its lead MB-204 asset by Zhejiang Ausun Pharmaceutical Co., Ltd. ("Ausun"). The engineering run material will be used for its ongoing toxicology studies of MB-204 being conducted by Pharmaron Inc. ("Pharmaron"). Pharmaron's whos

    • Newsfile

      Marvel Biosciences Achieves CGMP Milestone and Begins IND-Enabling Pre-Clinical Toxicology Testing of Lead Compound

      Calgary, Alberta--(Newsfile Corp. - December 8, 2021) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that it has initiated its pre-clinical investigational new drug ("IND") enabling toxicology studies for its lead compound MB-204 with Pharmaron, Inc. ("Pharmaron"), with its principal office in Louisville, Kentucky.Pharmaron, one of the world's largest contract research organizatio

    • ACCESSWIRE

      Keynotes, Educational Panels and 70 Companies to Present at the SNN Network Canada Virtual Event on December 7-9, 2021

      LOS ANGELES, CA / ACCESSWIRE / December 6, 2021 / The SNN Network Canada Virtual Event will take place on December 7-9, 2021, where 70 SmallCap, MicroCap and NanoCap public and private companies will be presenting via virtual webcast to a global investor audience.The SNN Network Canada Virtual Event begins on Tuesday, December 7, 2021 with the "MicroCap Investing Workshop" starting at 8:00am EST and featuring well-known financial influencers, investors, fund managers, and key opinion leaders inc

    Advertisement
    Advertisement